Evidence map›Paper›PMID 35662315›Full record

ReviewJournal of cardiovascular electrophysiology2022

Process mapping strategies to prevent subcutaneous implantable cardioverter-defibrillator infections.

Raul Weiss, George E Mark, Mikhael F El-Chami, Mauro Biffi, Vincent Probst, Pier D Lambiase, Marc A Miller, Timothy McClernon, Linda K Hansen, Bradley P Knight and 2 more

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of cardiovascular electrophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 4 countries.

Raul WeissDepartment of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID 0000-0003-1489-4028
George E MarkDepartment of Cardiology, Cooper University Hospital, Camden, New Jersey, USA.
Mikhael F El-ChamiDivision of Cardiology, Section of Electrophysiology, Emory University Hospital, Atlanta, Georgia, USA.ORCID 0000-0003-4978-7177
Mauro BiffiUniversity of Bologna, and Azienda Ospedaliera di Bologna, Bologna, Italy.
Vincent ProbstL'Institut du Thorax, Cardiologic Department and Reference Center for Hereditary Arrhythmic Diseases, Nantes, France.
Pier D LambiaseUCL Institute of Cardiovascular Science, and Barts Heart Center, London, UK.
Marc A MillerIcahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, New York, USA.ORCID 0000-0001-7512-4727
Timothy McClernonPeople Architects Inc., Minneapolis, Minnesota, USA.
Linda K HansenBoston Scientific, St. Paul, Minnesota, USA.
Bradley P KnightMedical Director of Cardiac Electrophysiology, Center for Heart Rhythm Disorders Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Chicago, Illinois, USA.
Larry M BaddourDepartment of Medicine, Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
other members of the S-ICD Process Mapping Consortium
Azienda USL di Bologna · ITBoston Scientific (United States) · USBritish Heart Foundation · GBCooper University Hospital · USEmory University Hospital · USInstitut du Thorax · FRMayo Clinic · USMount Sinai Hospital · USNorthwestern Memorial Hospital · USPeople for Parks · USThe Ohio State University Wexner Medical Center · US

Funding

Boston Scientific Corporation
6 · The paper itself

Abstract

backgroundInfection remains a major complication of cardiac implantable electronic devices and can lead to significant morbidity and mortality. Implantable devices that avoid transvenous leads, such as the subcutaneous implantable cardioverter-defibrillator (S-ICD), can reduce the risk of serious infection-related complications, such as bloodstream infection and infective endocarditis. While the 2017 AHA/ACC/HRS guidelines include recommendations for S-ICD use for patients at high risk of infection, currently, there are no clinical trial data that address best practices for the prevention of S-ICD infections. Therefore, an expert panel was convened to develop a consensus on these topics.

methodsAn expert process mapping methodology was used to achieve consensus on the appropriate steps to minimize or prevent S-ICD infections. Two face-to-face meetings of high-volume S-ICD implanters and an infectious diseases specialist, with expertise in cardiovascular implantable electronic device infections, were conducted to develop consensus on useful strategies pre-, peri-, and postimplant to reduce S-ICD infection risk.

resultsExpert panel consensus on recommended steps for patient preparation, S-ICD implantation, and postoperative management was developed to provide guidance in individual patient management.

conclusionAchieving expert panel consensus by process mapping methodology for S-ICD infection prevention was attainable, and the results should be helpful to clinicians in adopting interventions to minimize risks of S-ICD infection.

Indexed as

Defibrillators, ImplantableConsensusDeath, Sudden, CardiacHumansTreatment Outcomeantibiotic prophylaxisantibioticsdefibrillatorinfectionmappingpreventionsubcutaneous implantable cardioverter-defibrillatorsurgical site infection

Identifiers

PMID35662315
PMCPMC9544305
OpenAlexW4281753954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.